Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 2, 2015 - Issue
Submit an article Journal homepage
70
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

Sangheun Lee1 Department of Internal Medicine, International St Mary’s Hospital, Catholic Kwandong University, Incheon Metropolitan City, Republic of Korea
,
Beom Kyung Kim2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;3 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea;4 Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea;5 Liver Cirrhosis Clinical Research Center, Seoul, Republic of Korea
,
Seung Up Kim2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;3 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea;4 Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea;5 Liver Cirrhosis Clinical Research Center, Seoul, Republic of KoreaCorrespondence[email protected]
,
Jun Yong Park2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;3 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea;4 Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea;5 Liver Cirrhosis Clinical Research Center, Seoul, Republic of Korea
,
Do Young Kim2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;3 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea;4 Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea;5 Liver Cirrhosis Clinical Research Center, Seoul, Republic of Korea
,
Sang Hoon Ahn2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;3 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea;4 Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea;5 Liver Cirrhosis Clinical Research Center, Seoul, Republic of Korea;6 Brain Korea 21 Project for Medical Science, Seoul, Republic of Korea
&
Kwang-Hyub Han2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;3 Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea;4 Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea;5 Liver Cirrhosis Clinical Research Center, Seoul, Republic of Korea;6 Brain Korea 21 Project for Medical Science, Seoul, Republic of Korea
 show all
Pages 39-47 | Published online: 28 Apr 2015

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Shaoming Song, Mingzhen Bai, Xiaofei Li, Shiyi Gong, Wenwen Yang, Caining Lei, Hongwei Tian, Moubo Si, Xiangyong Hao & Tiankang Guo. (2022) Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. Expert Review of Molecular Diagnostics 22:3, pages 361-378.
Read now
Rachael Chang Lee & Niall Tebbutt. (2019) Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. Expert Review of Anticancer Therapy 19:4, pages 343-353.
Read now
Marina G Tarakanovskaya, Jigjidsuren Chinburen, Purev Batchuluun, Chogsom Munkhzaya, Genden Purevsuren, Dorjiin Dandii, Tsogkhuu Hulan, Dandii Oyungerel, Galyna A Kutsyna, Alan A Reid, Vika Borisova, Allen I Bain, Vichai Jirathitikal & Aldar S Bourinbaiar. (2017) Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. Journal of Hepatocellular Carcinoma 4, pages 59-69.
Read now

Articles from other publishers (13)

Claudia Campani, Jessica Bamba‐Funck, Bertille Campion, Sabrina Sidali, Lorraine Blaise, Nathalie Ganne‐Carrié, Alix Demory, Olivier Sutter, Edouard Larrey, Manon Evain, Haroun Ghannouchi, Mathilde Wagner, Fabio Marra, Angela Sutton, Manon Allaire & Jean‐Charles Nault. (2022) Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab . Liver International 43:3, pages 708-717.
Crossref
Landon L. Chan & Stephen L. Chan. (2023) The combination of ALBI and AFP response: A small step forward in HCC . Liver International 43:2, pages 271-273.
Crossref
Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, Yutaka Yasui, Hironori Ochi, Toshie Mashiba, Azusa Sakamoto, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Nami Mori, Shintaro Takaki, Keiji Tsuji, Haruhiko Kobashi, Atsunori Kusakabe, Koichiro Furuta, Hirotaka Arai, Michiko Nonogi, Chikara Ogawa, Takashi Sato, Takashi Tamada, Shinichiro Nakamura, Chitomi Hasebe, Kaoru Tsuchiya & Namiki Izumi. (2022) Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Investigational New Drugs 40:6, pages 1290-1297.
Crossref
Andrew X. Zhu, Farshid Dayyani, Chia-Jui Yen, Zhenggang Ren, Yuxian Bai, Zhiqiang Meng, Hongming Pan, Paul Dillon, Shivani K. Mhatre, Vincent E. Gaillard, Sairy Hernandez, Robin Kate Kelley & Bruno Sangro. (2022) Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research 28:16, pages 3537-3545.
Crossref
Linbin Lu, Lujun Shen, Zhixian Wu, Yanhong Shi, Peifeng Hou, Zengfu Xue, Cheng Lin & Xiong Chen. (2022) Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study. eClinicalMedicine 47, pages 101391.
Crossref
Lei Xu, Lin Chen & Wei Zhang. (2021) Neoadjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery 13:12, pages 1550-1566.
Crossref
Katharina Carolin Albrecht, René Aschenbach, Ioannis Diamantis, Niklas Eckardt & Ulf Teichgräber. (2020) Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres. Journal of Cancer Research and Clinical Oncology 147:1, pages 23-32.
Crossref
Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong-Won Park, Thomas Yau, Stephen L. Chan, Jean-Frederic Blanc, Vincent C. Tam, Albert Tran, Vincenzo Dadduzio, David W. Markby, Rajesh Kaldate, Ann-Lii Cheng, Anthony B. El-Khoueiry & Ghassan K. Abou-Alfa. (2020) Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research 26:18, pages 4795-4804.
Crossref
Yu‐Yun Shao, Tsung‐Hao Liu, Chiun Hsu, Li‐Chun Lu, Yin‐Chung Shen, Zhong‐Zhe Lin, Ann‐Lii Cheng & Chih‐Hung Hsu. (2019) Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International 39:11, pages 2184-2189.
Crossref
Ali A. Mokdad, Hao Zhu, Muhammad S. Beg, Yull Arriaga, Jonathan E. Dowell, Amit G. Singal & Adam C. Yopp. (2019) Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. Targeted Oncology 14:5, pages 541-550.
Crossref
Chao He, Wei Peng, Xiaojuan Liu, Chuan Li, Xueting Li & Tian-Fu Wen. (2019) Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma. Medicine 98:31, pages e16557.
Crossref
Brian C. Grieb, Laura W. Goff, Lipika Goyal & Crystal S. Denlinger. (2019) Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. American Society of Clinical Oncology Educational Book:39, pages 248-260.
Crossref
Ian Chau, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frédéric Blanc, Masatoshi Kudo, Tulio Pfiffer, Etsuro Hatano, Hyun Cheol Chung, Katerina Kopeckova, Jean-Marc Phelip, Giovanni Brandi, Shinichi Ohkawa, Chung-Pin Li, Takuji Okusaka, Yanzhi Hsu, Paolo B. Abada & Andrew X. Zhu. (2018) Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer 119:1, pages 19-26.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.